-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
Silicon Publishing Launches Prism, Bringing AI-Assisted Automation to Database Publishing
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Moderna to Present at Upcoming Conference in November 2026
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
SNZweig Forms AEC Industry Advisory Council
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Berwyn Group Launches BerwynAPI, Bringing Real-Time Death Confirmation to a Broad Variety of Industries Including Financial Services, Insurance and Healthcare
-
Team Montlick Wins Class 2 World Championship Title in Key West
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.
The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs for New Employee 3 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 3's date of hire.
The RSUs for all three new employees were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Y.Kobayashi--AMWN